<DOC>
	<DOCNO>NCT02741388</DOCNO>
	<brief_summary>This open label , multicenter , dose escalation , phase Ib study determine recommend phase II dose ( RP2D ) , assess maximum tolerate dose ( MTD ) , safety preliminary efficacy selinexor adult patient relapsed/refractory B-cell malignancy receive either R-DHAOx ( Group A ) R-GDP ( Group B ) . This dose escalation phase follow exploratory expansion phase population 12 patient enrol group , receive selinexor RP2D . The `` 3+3 '' design apply dose escalation . The escalation perform independently two distinct group : - Group A : Oral selinexor + R-DHAOx 3 cycle ( 3-week cycle ) - Group B : Oral selinexor + R-GDP 3 cycle ( 3-week cycle ) The choice conventional immunotherapy regimen administer patient , R-DHAOx ( Group A ) R-GDP ( Group B ) , leave investigator 's decision patient 's inclusion . Different dose level selinexor administration examine sequentially group Dose Escalation Committee ( DEC ) : 4 dos selinexor per 3-week cycle 20 mg flat ( Dose Level -1 , DL-1 ) , 40 mg flat ( DL1 ) , 60 mg flat ( DL2 ) 80 mg flat ( DL3 ) take orally patient D1 , D3 , D8 D10 cycle ( dose week = week 1 week 2 3-week cycle ) . Dose escalation begin DL1 continue MTD exceed high dose level define study ( DL3 ) reach . Dose escalation next plan dose level decide DEC base number DLTs observe DLT assessment period . The dose escalation phase follow exploratory expansion phase two group ( Groups A B ) , depend decision Independent Data Monitoring Committee ( IDMC ) review safety data end dose escalation part . Patients enrolled expansion phase receive selinexor RP2D define IDMC , together either conventional regimen R-DHAOx R-GDP ( leave investigator 's choice ) .</brief_summary>
	<brief_title>A Phase Ib Study Oral Selinexor Adult Patients With Relapsed/Refractory B-cell Lymphoma Receiving R-DHAOx R-GDP</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<criteria>1 . Patients type relapsed refractory Bcell lymphoma 2 . Eligible receive RDHAOx RGDP regard investigator 's opinion 3. Who receive prior therapy least one two line therapy BCell Lymphoma 4 . Patient must measurable disease define least one single node tumor lesion &gt; 1.5 cm 5 . Aged 18 year 70 year ( include ) date consent signature 6 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 2 7 . With life expectancy ≥ 3 month 8 . Having sign write informed consent 9 . Male patient ( sexually active woman childbearing potential ) must agree use reliable method birth control study treatment least 6 month last study drug administration . Male patient must agree donate sperm study treatment least 6 month last study drug administration 10 . Female patient childbearing potential must agree use two reliable method birth control study treatment 6 month last dose negative serum human chorionic gonadotropin ( hCG ) pregnancy test within 3 day prior C1D1 . Reliable method contraception include intrauterine device , hormonal contraceptive [ contraceptive pill , implant , transdermal patch , hormonal vaginal device injection prolong release ] , abstinence sterilization partner . 1 . Previous treatment selinexor 2 . Known central nervous system meningeal involvement lymphoma 3 . Contraindication drug contain regimen 4 . Subjects know Human Immunodeficiency Virus ( HIV ) positivity 5 . Subjects know active Hepatitis B ( HB ) infection ( positive Ag HBs ) positive serology hepatitis B ( Ag HBs antibody antiHB c positive DNA PCR ) active Hepatitis C ( HCV ) infection ( patient positive HCV serology eligible PCR negative know HCV RNA ) 6 . Subjects uncontrolled active systemic infection require intravenous ( IV ) antibiotics 7 . Any following laboratory abnormality within 14 day prior first administration ( C1D1 ) study treatment : 1 . Absolute neutrophil count ( ANC ) &lt; 1,000 cells/mm3 ( 1.0 x 109/L ) 2 . Spontaneous ( within 7 day platelet transfusion ) platelet count &lt; 100,000/mm3 ( 100 x 109/L ) ( 75 x 109/L due lymphoma ) 3 . Aspartate aminotransferase ( AST ) Alanine aminotransferase ( ALT ) &gt; 5.0 x upper limit normal ( ULN ) 4 . Serum total bilirubin &gt; 2x Upper Limit Normal ( ULN ) , &gt; 5x ULN due Gilbert syndrome lymphoma involvement 8 . Creatinine clearance &lt; 50 mL /min ( patient receive DHAOx ) &lt; 70 mL/min ( GDP ) 9 . Subjects preexist ≥ Grade 2 neuropathy 10 . Prior history malignancy lymphoma ( except basal cell squamous cell carcinoma skin situ carcinoma cervix breast ) unless subject free disease ≥ 3 year 11 . Any lifethreatening illness , serious active disease comorbid medical condition , laboratory abnormality , organ system dysfunction psychiatric illness , investigator 's opinion , could compromise patient 's safety , interfere absorption metabolism selinexor , put study outcome undue risk , would prevent subject signing informed consent form 12 . Pregnant breastfeed woman 13 . Use standard experimental anticancer drug therapy within 28 day initiation ( Day 1 ) study drug therapy ( administration glucocorticoid exceed 1mg/kg/day 14 day prior C1D1 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>selinexor</keyword>
	<keyword>lymphoma</keyword>
	<keyword>inhibitor nuclear export</keyword>
</DOC>